Max Healthcare: Business Overview & Financial Analysis

Max Healthcare Institute is the second-largest healthcare provider network in India by revenue and operating profit. Headquartered in New Delhi, the company operates a network of quaternary and super-speciality hospitals across North, West, and East India. Its core medical services include oncology, cardiac sciences, neurosciences, orthopaedics, renal care, and organ transplants, supported by diagnostic services through Max Lab and home healthcare through Max@Home.

Max Healthcare Key Operational Metrics (Q4 FY26)

Max Healthcare delivered strong operational performance during the quarter, supported by high occupancy levels, capacity expansion, and growing patient volumes.

• Operational Bed Capacity – 4,966 beds
• Bed Occupancy Rate – 75%
• Average Revenue Per Occupied Bed (ARPOB) – Rs 77,900
• Network Annualised EBITDA Per Bed – Rs 73.4 lakh
• Outpatient Consultations – 9.2 lakh visits

Operational bed capacity increased by 412 beds over the previous year to reach 4,966 beds as of March 2026. Bed occupancy remained healthy at 75%, while occupied bed days and outpatient consultations both grew 8% year-on-year.

Max Healthcare Geographic Network & Bed Capacity (Q4 FY26)

The company has a strong presence across major urban healthcare markets, supporting long-term growth and operational efficiency.

• Delhi NCR Cluster – 13 facilities (~65% of total bed capacity)
• Western Region (Mumbai & Nagpur) – 3 facilities (~18% of total bed capacity)
• Northern Region (Punjab, Uttarakhand & UP) – 5 facilities (~14% of total bed capacity)
• Eastern Region (Bhubaneswar) – 1 facility (~3% of total bed capacity)

Max Healthcare operates 21 healthcare facilities with over 6,000 capacity beds and 4,966 operational beds. During the year, the company acquired a 58.28% controlling stake in Kalinga Hospital in Bhubaneswar and continued expanding capacity through brownfield projects in Delhi, Mohali, and Mumbai.

Max Healthcare Clinical Speciality Revenue Mix (Q4 FY26)

The company generates a significant share of its revenue from high-end speciality treatments and complex surgical procedures.

• Oncology – 21% of IPD revenue
• Cardiac Sciences – 16% of IPD revenue
• Neurosciences – 11% of IPD revenue
• Orthopaedics & Joint Replacement – 10% of IPD revenue
• Renal Sciences & Urology – 9% of IPD revenue
• Gastrointestinal & Minimal Access Surgery – 8% of IPD revenue

Non-oncology hospital revenue grew 15% year-on-year during the quarter, reflecting healthy demand across major specialities. High-end procedures such as organ transplants and robotic surgeries continue to support higher revenue per occupied bed.

Max Healthcare Payor Mix & Patient Acquisition Channels (Q4 FY26)

The company has a diversified patient base supported by self-pay customers, insurance, and digital channels.

• Self-Pay Cash & Insured Patients – ~65% of bed share
• Institutional Scheme Patients – 35.5% of bed share
• International Medical Tourism Revenue – Rs 227 crore (9% of hospital revenue)
• Digital Channel Revenue – Rs 838 crore (31% of gross revenue)

International patient revenue increased 12% year-on-year to Rs 227 crore. Digital channels also continued to gain traction, contributing 31% of gross revenue through online appointments and lead generation.

Max Healthcare Consolidated Financial Performance (Q4 FY26 & FY26)

The company delivered strong revenue growth and healthy profitability during both the quarter and the full financial year.

• Q4 Gross Revenue – Rs 2,664 crore (+10% YoY)
• Q4 Operating EBITDA – Rs 682 crore (+8% YoY)
• Q4 Operating EBITDA Margin – 26.8%
• Q4 Network Profit After Tax (PAT) – Rs 387 crore (+3% YoY)
• Full Year FY26 Gross Revenue – Rs 10,538 crore (+16% YoY)
• Full Year FY26 Network PAT – Rs 1,631 crore (+22% YoY)

Consolidated revenue from operations increased 12.2% year-on-year to Rs 2,142.89 crore during Q4 FY26. Higher patient volumes, additional bed capacity, and strong operating cash flows supported the company's financial performance, while the Board recommended a final dividend of Rs 2 per equity share.

Max Healthcare Non-Hospital Business Performance (Q4 FY26)

The company's diagnostic and home healthcare businesses continued to expand alongside its hospital network.

• • Max Lab Revenue – Rs 52 crore (+14% YoY)
• • Max@Home Revenue – Rs 73 crore (+30% YoY)
• • Max Lab Geographic Footprint – 60+ cities
• • Max Lab Diagnostic Portfolio – 2,700+ tests

Max Lab continued expanding its diagnostic services across more than 60 cities, while Max@Home recorded strong growth driven by increasing demand for home nursing, physiotherapy, critical care, and medicine delivery services.

Max Healthcare Capex & Capacity Expansion Roadmap (FY2026–FY2030)

The company is investing heavily to significantly increase its hospital capacity over the coming years.

• Current Operational Capacity – 4,966 beds
• Lucknow Greenfield Outlay – ~Rs 1,400 crore (712 beds)
• Gurugram Greenfield Project – 500 beds
• Total Pipeline Bed Target – 10,000+ beds
• Quarterly Expansion Capex (Q4 FY26) – Rs 328 crore

Max Healthcare continues expanding through both greenfield and brownfield projects. New facilities in Lucknow and Gurugram, along with ongoing expansions at existing hospitals, are expected to help the company more than double its operational bed capacity over the long term.

Max Healthcare Management Commentary & Strategic Guidance (FY2026–FY2027)

Management remains focused on expanding capacity, improving operating leverage, and strengthening its regional presence.

• Operating EBITDA Margin Guidance – Maintain margins in the 26%–27% band
• Capacity Ramp-up Target – Expand operational beds at Max Lucknow from 426 to 570 beds
• Talent Acquisition Plan – Continue clinical hiring to support greenfield projects in Gurugram and Mohali
• Long-Term Network Goal – Scale total operational bed count to over 10,000 beds

Management expects margins to remain stable as newly added beds achieve higher occupancy. The company will continue expanding through brownfield projects while integrating Kalinga Hospital and strengthening its tertiary care capabilities.

Sources & References

• Max Healthcare Institute Q4 FY26 Financial Results & Press Release (May 2026)
• Max Healthcare Institute Investor Presentation (May 2026)
• Max Healthcare Institute Q4 FY26 Earnings Call Transcript
• BSE India Official Regulatory Announcements & Filings
• Ticker Finology Data & Disclosures

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.

Disclaimer
The information presented above on Max Healthcare has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Max Healthcare page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.